Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis Corrigendum in /10.3892/ol.2017.6082

Holmsten,Karin; Hammer Dohn,Line; Jensen,Niels Viggo; Shah,Carl‑Henrik; Jäderling,Fredrik; Pappot,Helle; Ullén,Anders

doi:10.3892/ol.2016.4775

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

Corrigendum in: /10.3892/ol.2017.6082

Authors:
- Karin Holmsten
- Line Hammer Dohn
- Niels Viggo Jensen
- Carl‑Henrik Shah
- Fredrik Jäderling
- Helle Pappot
- Anders Ullén
View Affiliations

Affiliations: Department of Oncology and Pathology, Karolinska University Hospital, SE‑171 76 Stockholm, Sweden, Department of Oncology, Rigshospitalet, 2100 Copenhagen, Denmark, Department of Oncology, Odense University Hospital, 5000 Odense, Denmark, Department of Radiology, Karolinska University Hospital, SE‑171 76 Stockholm, Sweden
Published online on: June 23, 2016 https://doi.org/10.3892/ol.2016.4775
Pages: 1293-1300
Copyright: © Holmsten et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In 2009, vinflunine was introduced as a second‑line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retrospectively from the first 100 mUC patients treated with vinflunine at three Nordic cancer centers associated with the Nordic Urothelial Cancer Oncology Group. The overall response rate was 23% and complete response was observed in one patient. The median progression‑free survival (mPFS) and median overall survival (mOS) were 2.8 (range, 0.5‑34.3) and 6.3 (range, 0.3‑39.7) months, respectively. An Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 was present in 20% of the patients, and those patients exhibited significantly shorter mOS (4.1 vs. 7.0 months, P=0.001) and a significantly higher degree of grade 3/4 toxicity (P=0.026) compared with ECOG PS 0‑1 patients. Furthermore, patients without visceral metastases had significantly longer mOS than patients with visceral metastases (10.6 vs. 6.0 months, P=0.008). The median number of cycles of vinflunine was 3 (range, 1‑28). The current data confirms that vinflunine is an active agent for second‑line treatment in an unselected clinical cohort of patients with mUC. ECOG PS and presence of visceral metastases were significant prognostic parameters. In particular, patients with ECOG PS 2 receiving vinflunine had a shorter mOS and a higher frequency of severe toxicity, and, thus, should be treated with caution. Furthermore, the present study observed large inter-individual differences in radiological response and OS, indicating the need for further development of improved patient selection tools to optimize vinflunine treatment in platinum‑refractory mUC patients.

View Figures

View References

1	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.PubMed/NCBI
2	Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M and De Lena M: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 34:1208–1212. 1998. View Article : Google Scholar : PubMed/NCBI
3	McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 15:1853–1857. 1997.PubMed/NCBI
4	Roth BJ, Manola J, Dreicer R, Graham D and Wilding G: Eastern Cooperative Oncology Group: Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): A phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 20:425–429. 2002. View Article : Google Scholar : PubMed/NCBI
5	Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL and Loehrer PJ Sr: Topotecan in previously treated advanced urothelial carcinoma: An ECOG phase II trial. Invest New Drugs. 16:191–195. 1998. View Article : Google Scholar : PubMed/NCBI
6	Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, et al: Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 30:507–512. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM and Bajorin DF: Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 28:1373–1379. 2010. View Article : Google Scholar : PubMed/NCBI
8	Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C and Otto T: A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 29:2870–2876. 2012. View Article : Google Scholar : PubMed/NCBI
9	Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C and Vaishampayan U: A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 11:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
10	Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, et al: Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers. Ann Oncol. 23:2663–2670. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F and El-Hariry IA: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 115:2881–2890. 2009. View Article : Google Scholar : PubMed/NCBI
12	Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 27:4454–4461. 2009. View Article : Google Scholar : PubMed/NCBI
13	Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S and Choueiri TK: Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 24:1466–1472. 2013. View Article : Google Scholar : PubMed/NCBI
14	Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, Ribal MJ, van der Heijden AG and Sherif A: European Association of Urology: EAU guidlines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
15	Razzak M: Urothelial carcinoma: Vinflunine offers modest but important survival benefit. Nat Rev Urol. 10:1862013. View Article : Google Scholar : PubMed/NCBI
16	Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C and Otto T: Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs. 24:422–425. 2013. View Article : Google Scholar : PubMed/NCBI
17	Clinical Trials.gov. Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR). https://clinicaltrials.gov/ct2/show/NCT01844947Accessed. March 17–2014
18	Sonpavde G, Jones BS, Bellmunt J, Choueiri TK and Sternberg CN: Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 29:361–376. 2015. View Article : Google Scholar : PubMed/NCBI
19	Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ and Rosenberg JE: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 28:1850–1855. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, et al: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 63:717–723. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, et al: A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 113:E137–E143. 2014. View Article : Google Scholar : PubMed/NCBI
22	Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y and Choueiri TK: Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 48:1495–1502. 2012. View Article : Google Scholar : PubMed/NCBI
23	Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, et al: Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: Implications for trial design. Clin Genitourin Cancer. 11:495–500. 2013. View Article : Google Scholar : PubMed/NCBI
24	Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G and Boyle MG: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 17:3173–3181. 1999.PubMed/NCBI
25	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
26	Punt CJ, Buyse M, Köhne CH, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L, Sobrero A and Douillard JY: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 99:998–1003. 2007. View Article : Google Scholar : PubMed/NCBI
27	U.S. Department of Health and Human Services: National Institutes of Health. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. 2009.
28	De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 30:191–199. 2012. View Article : Google Scholar : PubMed/NCBI